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1. INTRODUCTION 1 
 The landscape of the surgical management of urologic malignancies has dramatically 2 
changed over the past 20 years. On one side, better diagnostic and prognostic tools allowed better 3 
patient  selection and more reliable surgical planning. On the other hand, the implementation of 4 
minimally invasive techniques and technologies, such as robot-assisted laparoscopy surgery and 5 
image-guided surgery, allowed minimizing surgical morbidity. Ultimately, these advances have 6 
translated into a more tailored approach to the management of urologic cancer patients. Following 7 
the paradigm of “precision medicine”, contemporary urologic surgery has entered a technology-8 
driven era of “precision surgery”, which entails a range of surgical procedures tailored to combine 9 
maximal treatment efficacy with minimal impact on patient function and health related quality of 10 
life1. The aim of this non-systematic review is to provide a critical analysis of the most recent 11 
advances in the field of surgical uro-oncology, and to define the current and future role of 12 
“precision surgery” in the management of genitourinary cancers, with a focus on prostate, bladder 13 
and kidney cancer. 14 
 15 
2. PROSTATE CANCER 16 
 Prostate cancer continues to have a high incidence in most industrialized countries, despite  17 
decreasing mortality rates2. Standardization in multi parametric MRI techniques allowed better 18 
identification of clinically significant cancers3, as well as better disease staging4. Active 19 
surveillance has taken the stage and has been implemented with different protocols worldwide for 20 
very low-risk, low-risk, and selected intermediate-risk disease5,6. A better understanding of tumor 21 
biology and the availability of novel prognostic and diagnostic tools have significantly changed the 22 
paradigm in the management of this disease. Several genomic tests - such as Prolaris®, Oncotype 23 
DX®, and Decipher® - are already commercially available, and are now being used, in addition to 24 
traditional clinical nomograms, although their role is yet to be defined7. Recent introduction of 3D 25 
printing technology might further facilitate surgical planning (Figure 1).  26 
 After the golden era of laparoscopic prostate surgery, modern prostate cancer surgery has 27 
been mainly driven by the rapid adoption of robot-assisted laparoscopy radical prostatectomy 28 
(RARP)8, 9, which now represents the gold standard treatment option in most industrialized 29 
countries10, 11. Moreover, the implementation of multi-parametric MRI imaging to prostate biopsy 30 
techniques12 (Figure 2) has paved the way to the concept of “focal therapy”13. This paragraph will 31 
be focused on these two main areas of clinical interest.  32 
2.1. Robotic surgery for prostate cancer 33 
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2.1.1. Refinements in RALP technique 1 
 One of main advantages of robotic surgery is certainly represented by the magnification of 2 
the surgical field, allowing a better visualization and easier appreciation of fine anatomical details. 3 
Overall, a better understanding of surgical anatomy of the prostate has translated into recognition of 4 
key anatomical structures, and its possible variations. Thus, the RARP procedure can be regarded as 5 
an individualized operation that can be tailored to the specific characteristics of the patient and the 6 
cancer14. The “trifecta” (cancer control, continence, and potency) has become the standard metrics 7 
to assess the outcomes of RARP15, as patient reported health related quality of life is regarded as an 8 
important parameter to consider in prostate cancer treatment16. Therefore, refinements in surgical 9 
technique have been mainly directed towards the preservation of patient’s functions, namely urinary 10 
continence and sexuality.  11 
 Factors contributing to the continence status of men undergoing prostate cancer surgery 12 
have been extensively investigated. Besides preoperative parameters (such as age, prostate size, 13 
membranous urethral length, and BMI), the impact of surgical dissection, damage to neurovascular 14 
bundles, and postoperative fibrosis have been recognized (Figure 3)17. Several techniques aiming at 15 
restoring the disrupted anatomy secondary to the removal of the prostate gland have been 16 
investigated (Table 1)18-30. These techniques are based on three key concepts: preservation (bladder 17 
neck sparing, puboprostatic ligaments, puboprostatic collar, pubovesical complex, urethral length); 18 
reconstruction (posterior and/or anterior reconstruction) (Figure 4); reinforcement (bladder neck 19 
plication and/or sling suspension)31. This has also resulted in a debate on the use of a standard 20 
nomenclature – such as the one proposed by the ESUT - to facilitate outcome comparisons and 21 
surgical education32. 22 
 Sexual dysfunction can represent a common clinical issue in patients undergoing prostate 23 
cancer surgery33. Several factors contribute to postoperative recovery of erectile function, including 24 
patient characteristics (age, baseline erectile function, co-morbidities), surgical technique (non- 25 
versus uni-or bilateral nerve sparing; extrafascial versus inter- or intrafascial), and surgeon factors 26 
(surgical volume and skills)34 (Figure 5). Despite extensive research in the field of prostate 27 
anatomy, controversies remain in regard to the location, distribution and function of periprostatic 28 
nerve fibers. Certainly, it is not possible to reproduce exactly the same dissection in every patient, 29 
and therefore the surgeon has to find for each case the best balance between an oncologic safe 30 
margin and the anatomical integrity of the nervous system (Figure 6). As anatomical knowledge 31 
has increased, there has been a shift from the simplistic dichotomy “non-nerve sparing versus nerve 32 
sparing” or “intra-inter-extra-fascial” towards the concept of “incremental nerve sparing” or 33 
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“incremental safety margin”14. In this regard, grading systems have been proposed to define the 1 
extent of tissue margin on the prostate10, 35, 36. Tewari et al proposed four grades of dissection by 2 
using the veins on the lateral aspect of the prostate as a vascular landmark35. Patel and coworkers 3 
proposed an inverse (grade 5 optimal nerve sparing, grade 1 no nerve sparing) five-grade scale by 4 
using the arterial periprostatic vasculature as landmark and by identifying a “landmark” artery36.  5 
 The concept that cautery-free dissection or pinpointed low-energy cauterization should be 6 
implemented when aiming at nerve preservation is well established33. In addition to this, 7 
investigators have explored several other technical refinements that would minimize nerve damage. 8 
Some noted that counter-traction on the neurovascular bundle (done by either the assistant or the 9 
console surgeon) might translate into neuropraxia and delayed recovery of sexual function37. A 10 
Retzius-sparing approach pioneered by Bocciardi and coworkers in order to perform the entire 11 
procedure through the pouch of Douglas might translate into higher potency rates38. The Martini 12 
Clinic group described a safe and effective way of performing  intraoperative neurovascular 13 
structure-adjacent frozen section examination (so called “NeuroSAFE”) during RARP39. More 14 
recently, Patel et al showed that the placement of dehydrated human amnion/chorion membrane 15 
around the neurovascular bundle can translate into earlier return of potency40. Other technologies 16 
are being investigated to facilitate precise identification of periprostatic nervous structures, such as 17 
fluorescence imaging and confocal laser endomicroscopy41. 18 
2.1.2. RARP: long term oncological data and comparison with open surgery 19 
 More than 15 years have passed since RARP was first described42, and mature data are now 20 
available showing that the procedure is effective in long term cancer control, even in  patients with 21 
high risk disease (Table 2)43-49.   22 
 Theoretically, robot-assisted surgery should be the ideal model to determine the impact and 23 
limitations of “surgical precision” providing better ergonomic for the surgeon, particularly during 24 
reconstructive steps, better vision and magnification during dissection of the prostate and 25 
surrounding anatomical details. Nevertheless, there is still a debate on “robotic versus open 26 
surgery” for prostate cancer mainly fuelled by large population based data analyses (Table 3)50-56. 27 
Hu et al reported two large analyses from the SEER Medicare dataset. They found that RARP is 28 
associated with lower likelihood of positive surgical margins for intermediate-risk (15.0% vs 29 
21.0%; OR: 0.66) and high-risk (15.1% vs 20.6%; OR: 0.70) disease, as well as less use of 30 
additional cancer therapy (at 24 months OR: 0.67)50. Moreover, they found that RARP is associated 31 
with an equivalent risk of all cause (HR 0.85) and cancer specific (HR 0.85) mortality55.  32 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
 In another large retrospective analysis of administrative data Leow et al looked at outcomes 1 
and costs of over 600,000 radical prostatectomies done in the USA over a 10-year period52. First of 2 
all, they found utilization of robotic surgery rapidly increased from 1.8% in 2003 to 85% in 2013 3 
(p<0.001). Moreover, RARP patients were less likely to experience complications ([OR 0.68, 4 
p<0.001) or to receive blood products (OR 0.33, p=0.002). While 90-day direct hospital costs were 5 
higher for RARP, costs were no longer significantly different between open and robotics for the 6 
highest-volume surgeons (≥104 cases/yr; +$1990, p=0.40) and hospitals (≥318 cases/yr; +$1225, 7 
p=0.39). Haglind et al reported a large prospective controlled nonrandomized trial involving 14 8 
Centers from Sweden and comparing robotic (n=1,847) to open (n=778) radical prostatectomy51. 9 
They could only find a modest benefit of robotic surgery for preservation of erectile function, 10 
whereas no difference was found in terms of continence and positive margin rates. Seo et al 11 
reported the latest systematic review and meta-analysis of studies comparing open to robotic 12 
surgery for prostate cancer53. They included 61 studies, and confirmed that RARP carries a lower 13 
risk of complications and urinary incontinence, as well as higher potency rate, whereas positive 14 
margin rates and recurrence-free survival were similar. However, the authors pointed out the low 15 
quality of available studies.  16 
 Moreover, they did not include the only available randomized controlled trial, which was 17 
recently reported by Yaxley et al. from the Royal Brisbane and Women's Hospital (Brisbane, 18 
Australia)54. Primary outcomes were urinary function and sexual function at 6 weeks, 12 weeks, and 19 
24 months and oncological outcome (positive surgical margin status and biochemical and imaging 20 
evidence of progression at 24 months). The trial was powered to assess health-related and domain-21 
specific quality of life outcomes over 24 months. In this preliminary report the authors reported the 22 
early outcomes at 6 weeks and 12 weeks. Overall, 151 in the radical retropubic prostatectomy group 23 
proceeded to surgery and 157 in the RARP group. Urinary function scores did not differ 24 
significantly between the radical retropubic prostatectomy group and RARP group at 6 weeks post-25 
surgery (p=0.09) or 12 weeks post-surgery (p=0.48). Sexual function scores also did not differ 26 
significantly between the groups at 6 weeks (p=0.45) or 12 weeks (p=0.18) post-surgery. There was 27 
also no difference for  proportion of positive surgical margins between the two groups (10% for 28 
open and 15% for robotic, p=0.21), as well as for postoperative complications (9% for open and 4% 29 
for robotic, p=0.052). Obviously, these findings generated different interpretations. As there was no 30 
difference between the two technique one might argue that the application of robotic surgery does 31 
not provide any benefit to the patient. On the other hand, by taking a close look, few important 32 
points need to be pointed out. The two surgeons involved in the trial had a very different surgical 33 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
experience as one had performed about 200 robotic cases (in 2 years) and the other over 1500 open 1 
cases (in 15 years) at the start of the trial. Thus, it can be argued that robotic surgery allowed the 2 
less experienced surgeon to achieve equal outcomes significantly faster. This concept is also 3 
supported by the findings from the study by Thompson et al, who analyzed over 1550 cases to 4 
determine whether a well established open surgeon (over 3,000 cases) could achieve better 5 
outcomes by switching to robotics. They found that, after a learning curve, the surgeon could indeed 6 
improve, especially their functional outcomes56. 7 
2.1.3. New frontiers of prostate cancer surgery: oligometastatic cancer and nodal recurrent 8 
cancer 9 
 Over the past years, oligometastatic cancer - clinically defined as disease with up to five 10 
extra-pelvic lesion - as has been recognized as separate clinical entity from advanced cancer, mostly 11 
thanks to the implementation of functional imaging57. A growing body of evidence seems to support 12 
the hypothesis that a radical treatment to their primary tumor, alongside “metastasis-directed 13 
therapy”, might be beneficial for patients with oligometastatic cancer. These has been suggested by 14 
recent large population-based studies, from both USA58 and Europe59.  Gandaglia et al reported on 15 
the outcomes of a selected cohort of 11 patients with oligometastatic disease treated with radical 16 
prostatectomy and extended pelvic lymph node dissection. Adjuvant androgen deprivation therapy 17 
was administered to 10 patients (91%). The 7-yr clinical progression-free and cancer specific 18 
survival survival rates were 45% and 82%, respectively60. Ongoing trials. whose findings will be 19 
available within the next few years, will better define the best approach for oligometastatic prostate 20 
cancer (Table 4) (www.clinicaltrials.gov).   21 
 Salvage lymph node dissection has been recently proposed as possible treatment option in 22 
selected prostate cancer patients with disease recurrence limited to regional and/or retroperitoneal 23 
nodes61.  This novel therapeutic approach has become available due to recent advances in the field 24 
of nuclear medicine imaging modalities, such as PET/CT and PET/MRI62. Several centers have 25 
reported initial series with encouraging results (Table 5)63-67, but further clinical investigation is 26 
required. 27 
2.2. Focal therapy for prostate cancer 28 
 Focal therapy has been conceived as a minimally invasive tissue-preserving treatment 29 
strategy for localized prostate cancer68. The rationale supporting this strategy is mainly based on the 30 
concept of “index lesion”, and on the increased ability to detect this lesion (and to rule out high risk 31 
lesions) thanks to the standardization of MRI imaging-based biopsy techniques69. 32 
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 In a recent systematic review, Valerio et al analyzed 37 studies including over 3,200 patients 1 
in order to summarize the current evidence on different modalities of focal therapy for prostate 2 
cancer70. Overall, seven different sources of energy have been tested, with some of them (high-3 
intensity focused ultrasound [HIFU], cryotherapy, photodynamic therapy [PDT], brachytherapy) 4 
studied on larger samples, some others (laser interstitial thermotherapy [LITT], irreversible 5 
electroporation [IRE] still in a more preliminary stage of assessment (Table 6). Among these, HIFU 6 
and cryotherapy are those that have been mostly implemented in clinical practice. However, 7 
evidence supporting the use of newer technologies, such as PDT, in low risk cancer is being 8 
reported in large scale phase III studies71.  9 
 10 
3. BLADDER CANCER 11 
 Urothelial bladder cancer represents a complex disease with a high prevalence, and high 12 
morbidity and mortality if not optimally treated72. Traditionally, its best surgical treatment depends 13 
on the stage of the disease: for non muscle invasive cancer, transurethral resection (TURB) 14 
followed by induction and maintenance immunotherapy with intravesical BCG or chemotherapy 15 
represents the current standard73; for muscle-invasive cancer, radical cystectomy with neoadjuvant 16 
chemotherapy offers the best chance for cure, whereas in selected patients bladder-sparing 17 
modalities, consisting of transurethral resection with chemo-radiation, can be considered74.  18 
 Over the past decade, two major areas of research in the field of bladder surgery have been 19 
investigated, that of new optimal imaging technologies for non muscle invasive disease, and that of 20 
robotic surgery for the management of muscle invasive disease.  21 
3.1. Innovations in optical imaging technology 22 
 Precision surgery for bladder cancer patients mostly relies on initial diagnostic endoscopic 23 
accuracy. The current standard “white light cystoscopy” presents significant shortcomings, 24 
including suboptimal detection of flat lesion (carcinoma in situ), inaccurate tumor delineation to 25 
facilitate complete resection, challenging differential diagnosis with inflammatory lesions, and 26 
difficult determination of grade and stage. Therefore, novel technologies have been developed and 27 
implemented to aid the surgeon during endoscopic management of bladder cancer75. These can be 28 
broadly categorized in macroscopic (photodynamic diagnosis [PDD]; narrow band imaging [NBI]; 29 
post-processing of the endoscopic image [SPIES]) and microscopic (confocal laser endomicroscopy 30 
[CLE]; optical coherence tomography [OCT]) ones. 31 
 PDD is also known as “fluorescence” or “blue light” cystoscopy. It requires preoperative 32 
intravesical administration of a contrast agent (a protoporphyrin analogue), a blue light (380-480 33 
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nm) source, and specialized lens and camera.  PDD has been implemented in Europe for the past 1 
two decades using 5-aminolevulinic acid (5-ALA). Its derivative hexaaminolevulinate (HAL; 2 
Hexvix®/Cysview®) has become more recently available and it was approved by the FDA in 2010 3 
on the basis of a phase III trial showing a 16% reduction in rate of recurrence at 9 months versus 4 
white light cystoscopy76. PDD seems to provide a better detection of both papillary and flat 5 
appearing CIS lesions. Burger et al reported a meta-analysis of raw data from prospective studies on 6 
1345 patients, and they found that PDD detected significantly more Ta tumors (14.7%) and CIS 7 
lesions (40.8%) than standard cystoscopy. Moreover, about 25% patients with at least one 8 
additional Ta/T1 tumor was identified when using PDD, and in 26.7% of patients, CIS was detected 9 
only by PDD. Overall, recurrence rates up to 12 months were significantly lower with PDD (34.5% 10 
versus 45.4%)77. However, a prospective randomized multicenter study found no significant 11 
difference in tumor recurrence and progression when using PDD78. In another pooled analysis of 3 12 
phase III multicenter trials detection rate for CIS was 87% with PDD and 75% for standard 13 
cystoscopy79. However, no data to date have suggested that use of PDD translates into a reduction 14 
in disease progression. False positive can be regarded as a drawback of the technology, as they 15 
occur in 10-12% of patients76. 16 
 NBI is a technology that filters out the red spectrum of white light resulting in blue and 17 
green spectra that are preferentially absorbed by hemoglobin, thus enhancing the mucosal and sub-18 
mucosal vasculature without need of any dye. This technology has been incorporated into rigid and 19 
flexible scopes, which carry a toggling functionality between white light and NBI, allowing real 20 
time assessment of suspicious areas. The first study on NBI was reported by Herr and Donat in 21 
2008, suggesting a better detection rate than white light cystoscopy80. Since then, multiple other 22 
series have been reported. A recent meta-analysis of 8 studies including 1022 patients showed the 23 
sensitivity and specificity of NBI and white light cystoscopy to be 94% versus 85% and 85% versus 24 
87%, respectively81. Another recent meta-analysis demonstrated that NBI-TURB can reduce the 25 
risk of recurrence at 3 months, 1 year and 2 years82. The Clinical Research Office of the 26 
Endourological Society (CROES) conducted a prospective randomised single-blind multicentre 27 
study comparing NBI and white light in patients with primary non-muscle-invasive bladder cancer. 28 
Overall, 965 patients were enrolled in the study (481 underwent -assisted TURB and 484 received 29 
NBI-assisted TURB). In patients at low risk for disease recurrence, recurrence rates at 12 months 30 
were significantly lower in the NBI group (5.6% versus 27.3%; p=0.002)83. Similar results can be 31 
obtained by the use of SPIES, as the image quality and definition is similar to NBI41.  32 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
 While PDD, NBI and SPIES have been clinically implemented on a large scale, other 1 
technologies such as CLE and OCT are still considered investigational. CLE is a technology that 2 
allows real time microscopy of the mucosa, and, after being primarily used in gastroenterology, it 3 
has been recently approved for clinical use in the urinary tract as micro-endoscopy probes (up to 2.6 4 
mm in diameter) passing through the channel of a standard rigid cystoscope are now available84. 5 
Fluoroscein is used as contrast agent to be administered intravesically or intravenously. Pioneer 6 
work by Sonn et al showed that CLE is feasible and it can differentiate normal urothelium from 7 
bladder cancer85. Clinical data remain limited and further investigation is awaited.  OCT is another 8 
real time high-resolution imaging technology that provides cross sectional images of biologic 9 
tissues by relying on information gathered by reflected energy (similarly to B mode ultrasound). 10 
Current technology uses a 2.7 mm diameter probe that can be passed through the cystoscope 11 
allowing visualization of the different layers of the bladder wall and to distinguish benign from 12 
malignant characteristics. Few studies have assessed the classification of OCT-assisted cystoscopy 13 
of bladder lesions as benign or malignant with a sensitivity of 84-100% and a specificity of 65-14 
89%86. Moreover, another study found a 90% positive predictive value for tumor invasion into the 15 
lamina propria87. Also for OCT, clinical studies are going and further results awaited. 16 
3.2. Sexual and organ preserving approaches for radical cystectomy (RC) 17 
 Open RC with pelvic lymph node dissection still represents the gold standard treatment for 18 
non-metastatic muscle-invasive and selected high-risk non muscle-invasive bladder cancer88. With 19 
better understanding of neuro-functional anatomy, sexual-preserving RC techniques have been 20 
developed over the years in order to achieve superior functional outcomes, in both male and female 21 
patients with bladder cancer89 (Table 7). Long-term data on “prostate sparing” RC have shown that 22 
this can be an oncologically safe procedure with excellent functional results in a subset of carefully 23 
selected patients90. “Seminal vesicle” cystoprostatectomy also resulted in a high probability of 24 
preserving potency, without putting patients at unnecessary risk91. “Nerve sparing” radical 25 
cystoprostatectomy also showed to not compromise cancer control while providing improved 26 
postoperative quality of life92,93. In female patients, genital sparing cystectomy (with preservation of 27 
the uterus, vagina and ovaries) is feasible in selected women, and it can provide good functional 28 
outcome, better sexual function, and favorable oncological outcome94. A “nerve sparing” technique 29 
in female patients has also been obtained by avoiding damage to the proximal urethra and to 30 
preserve the autonomic innervation of the rhabdosphincter95. 31 
3.3. Robotic surgery for bladder cancer 32 
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 Since the first description by Menon et al. in 200396, robot-assisted radical cystectomy 1 
(RARC) has been adopted in several institutions worldwide97. Over the last decade, the debate has 2 
been mainly focused on the perioperative outcomes of RARC versus the open gold standard 3 
technique. A recent meta-analysis of 19 studies, including a total of 1779 patients (787 patients in 4 
the RARC group and 992 patients in the open group) suggested that, despite the longer operative 5 
time, patients undergoing RARC might benefit from lower complication rates, more lymph node 6 
yields, less estimated blood loss, lower need for transfusions, and shorter postoperative length of 7 
stay98. However, another meta-analysis including only the four available RCTs comparing open to 8 
RARC, with a total of 239 patients, all with extracorporeal urinary diversion, found no significant 9 
difference between techniques in terms of perioperative morbidity, length of stay, positive surgical 10 
margin, lymph node yield. RARC group had significantly lower estimated blood loss and wound 11 
complications, but again required significantly longer operating time99. Thus, further studies are 12 
needed to determine the benefit of the minimally invasive approach for radical cystectomy, and 13 
results from ongoing trials are largely awaited100. These trials have to focus on the difficulty of 14 
urinary diversion by the robot-assisted intra-corporeal approach as well as on the oncologic impact 15 
of the laparoscopic technique. 16 
 In this setting, one of the key-factor is certainly represented by the urinary diversion, as this 17 
is largely recognized as the surgical step most likely to be associated with occurrence of 18 
perioperative morbidity. During the early phase of RARC, extracorporeal urinary diversions were 19 
mostly preferred. Over the past 5 years, the evolution of robotic surgery has enabled urologic 20 
surgeons to perform urinary diversions intracorporeally101. Intracorporeal urinary diversion has the 21 
potential benefits of a smaller incision, reduced pain, decreased bowel exposure, and reduced risk of 22 
fluid imbalance. A study by the International Robotic Cystectomy Consortium found that patients 23 
undergoing intracorporeal diversion after RARC were at a lower risk of 90-day postoperative 24 
complication102.  25 
 Since radical cystecotmy represents a cancer surgery, oncological outcomes remain a 26 
primary concern. Only few series of minimally invasive radical cystectomy with long term 27 
oncological follow-up have been reported to date, with encouraging results103-105. Concerns 28 
regarding the pattern of recurrence after RARC, with one study showing more frequent extrapelvic 29 
lymph node locations and peritoneal carcinomatosis in RARC patients compared to open surgery 30 
patients106. In this regard, studies on laparoscopic series have advocated a potential risk associated 31 
with the use of pneumoperitoneum107. Nevertheless, a study on a recent large series of patients who 32 
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underwent RARC with intracorporeal urinary diversion at nine different institutions did not identify 1 
unusual recurrence patterns108.  2 
 3 
 4. KIDNEY CANCER 4 
 Despite a rising incidence, the mortality of RCC in developed countries has been stable over 5 
the last decade109. This phenomenon can be explained by the significant advances in the 6 
management of  the disease, including refinements in renal biopsy techniques110, implementation of 7 
active surveillance protocols111, and adoption of minimally invasive nephron-sparing surgery 8 
procedures112. This has resulted into a paradigm shift, which is the idea of tailoring the treatment to 9 
each specific case with the ultimate aim of achieving the best oncological outcome and the maximal 10 
functional preservation. This process has been facilitated by the application of new technologies, 11 
allowing a better surgical planning, within the realm of “precision surgery”. 12 
4.1. Expanding indications of nephron-sparing surgery and evolving role of robotic partial 13 
nephrectomy 14 
 Current clinical practice guidelines recommend partial nephrectomy (PN) as the gold 15 
standard treatment for small (clinical T1a) renal masses, given the advantages of nephron sparing 16 
surgery over radical nephrectomy in terms of renal function preservation113,114. Emerging data from 17 
centers of excellence as well as from national databases and meta-analyses have demonstrated 18 
oncological efficacy for larger masses (cT1b, cT2) with benefits in terms of renal functional 19 
preservation115-117. On the other hand, an overarching survival benefit from PN is more 20 
controversial with several retrospective and meta analyses suggesting a survival benefit while the 21 
sole randomized clinical (which closed due to poor enrollment and was thus underpowered) trial 22 
failing to demonstrate a survival benefit for partial nephrectomy despite improved renal functional 23 
outcomes in the partial nephrectomy arm118,119. 24 
 Despite the oncological equivalence to radical nephrectomy and renal functional benefit, PN 25 
has been regarded as a higher risk procedure with increased risk of urinary fistulae and procedure 26 
specific complications. This paradigm may be shifting however, with the increasing adoption of the 27 
robotic platform. Recent data suggest that robotic technology may enable surgeons across different 28 
practice settings to perform nephron-sparing surgery more frequently120.  29 
 The robotic approach offers the option of a minimally invasive PN recapitulating the safety 30 
and effectiveness of the open technique, which can still be regarded as the reference standard. The 31 
standardization of each surgical step has allowed for optimization of robotic PN procedure121. With 32 
increasing surgical experience, indications for robotic PN have significantly expanded to include 33 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
12 
 
more demanding clinical scenarios, such as completely intraparenchymal tumors121, hilar tumors122, 1 
and patients with previous ipsilateral nephron sparing procedure123.  2 
 Moreover, current evidence suggests that robotic PN can translate into better outcomes than 3 
conventional laparoscopic PN. A recent meta-analysis of 25 studies (including almost 5000 4 
patients) showed that patients treated with robotics presented larger (WMD 0.17 cm, p=0.001) and 5 
more complex (WMD 0.59 RENAL score, p=0.002) tumors. Nevertheless, robotic surgery was 6 
associated with a decreased likelihood of conversion (RR 0.36, p <0.001), and lower risk of 7 
complications (RR 0.84, p=0.007) and positive margins (RR 0.53, p <0.001), and shorter warm 8 
ischemia time (WMD 4.3 min, p <0.001)125.  Thus, robotics might replace laparoscopy as the most 9 
common minimally invasive approach for PN whenever the necessary technology is available126. 10 
However, in the hands of expert surgeons and with the aid of last new tools, such as 3D imaging 11 
and the ETHOS chair a more ergonomic position for the surgeon can facilitate the pure laparoscopy 12 
approach127. 13 
 From the standpoint of the surgical technique, the recent debate has been primarily focused 14 
on the management of the renal hilum. The recognized role of warm ischemia time as a modifiable 15 
factor impacting the postoperative renal functional outcome128 prompted several groups to explore 16 
the feasibility and safety of “zero-ischemia” (off clamp) and “minimal ischemia” (selective 17 
clamping) techniques129. With the increasing awareness regarding the preservation of healthy 18 
parenchyma as a major determinant of postoperative renal function130, another matter of debate has 19 
become the tumor resection technique. While the standard PN procedure implies the resection of a 20 
rim of renal parenchyma around the tumor, some groups have advocated “enucleation” 21 
techniques131 with the aim of maximizing preservation of nephrons while effectively removing the 22 
cancer (Figure 7).  23 
4.2. Tumor ablation techniques 24 
 With the aim of further minimizing the surgical morbidity, focal kidney ablation can be 25 
offered as an effective minimally invasive nephron-sparing treatment option. Several ablative 26 
technologies have been investigated to date; cryoablation and radiofrequency ablation (RFA) 27 
certainly represents the two modalities that have been most extensively implemented in clinical 28 
practice132, whereas other ablative procedures (microwave ablation, electroporation) are still 29 
investigational133-136 (Table 8).  30 
 Overall, probe-ablative therapy provides an attractive nephron-sparing treatment for small 31 
renal masses in older patients with significant medical co-morbidities who are poor candidates for 32 
standard extirpative surgery. In well selected patients, kidney ablation can offer several advantages, 33 
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including improved patient procedural tolerance, faster recovery, preservation of renal function, and 1 
reduction in the risk of complications. It is likely that outcomes associated with ablative modalities 2 
will improve with further advances in patient selection, technology and application. Emerging data 3 
suggest that for both cryoablation and RFA, patients with non-clear cell and lower grade histologies 4 
may have improved outcomes137. Patient counseling about thermal ablation should include a 5 
discussion of the risks of local recurrence, and potential need for re-intervention. Newer energy-6 
ablative modalities have the potential to become additional nephron-sparing options, but further 7 
investigation is needed. 8 
  9 
5. CONCLUSIONS 10 
 Over the past two decades, the paradigm of uro-oncological surgery has moved away from 11 
the obsolete principle of exclusively radical “one-size-fits-all” procedures. The current surgical 12 
therapy of the most common genitourinary cancers aims to combine the maximal oncological 13 
efficacy with the minimal impact on patient’s quality of life and functionality. A better knowledge 14 
of anatomy and cancer biology coupled with better diagnostic instruments allowed to improve 15 
surgical indications, to optimize surgical planning, and to tailor the surgical procedure to each 16 
specific patient. The application of novel technologies (robotic surgery, focal therapy, new imaging 17 
systems) have facilitated a minimally invasive approach in most of urologic cancer patients. We 18 
entered an era of “precision surgery”; nevertheless, the management of patients with genitourinary 19 
cancers remains suboptimal, and further translational research is needed to address many unmet 20 
needs in this field.  21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
29 
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FIGURE LEGENDS 1 
Figure 1. 3D printed prostate showing anterior T3 tumour close to sphincter (courtesy of Prof. 2 
Prokar Dasgupta, King's College London, Guy's Hospital, London, UK) 3 
Figure 2. MRI-US fusion transperineal prostate biopsy (courtesy of prof. Francesco Porpiglia, San 4 
Luigi Hospital, University of Turin, Orbassano, Italy) 5 
Figure 3. Factors contributing to urinary continence status post radical prostatectomy17 6 
Figure 4. Total (posterior and anterior) anatomical reconstruction during robot assisted radical 7 
prostatectomy (courtesy of prof. Francesco Porpiglia, San Luigi Hospital, University of Turin, 8 
Orbassano, Italy) 9 
Figure 5. Factors contributing to potency status post radical prostatectomy34 10 
Figure 6. Image guided nerve sparing robot assited radical prostatectomy (courtesy of prof. 11 
Francesco Porpiglia, San Luigi Hospital, University of Turin, Orbassano, Italy) 12 
Figure 7. Illustration of enucleation versus standard partial nephrectomy for the resection of renal 13 
tumors (dashed line=surgical plan of resection). 14 
 15 
 16 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 1. Overview of surgical techniques aiming at improved continence status after RALP 
Anatomical principle Reference Technique 
Preservation Friedlander18 Bladder neck sparing 
Lim30 Retzius sparing 
Reinforcement 
 
Lee24 Bladder neck plication stitch 
Bahler22 Small Intestinal Submucosa Bladder Neck Sling 
Lei19 Selective suture ligation of Dorsal venous complex 
Patel20 Periurethral suspension stitch 
Nguyen21 Urethral sling fashioned from autologous vas deferens 
Dal Moro27 Complete Reconstruction of the Posterior Urethral Support (CORPUS) 
Reconstruction Propiglia23 Total Anatomical Reconstruction  
Student25 Advanced reconstruction of vesicourethral support (ARVUS) 
Jeong26 1-step posterior reconstruction 
Hurtes28 Anterior retropubic suspension with posterior reconstruction 
Coelho29 Modified posterior reconstruction 
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Table 2. Ooncological outcomes of RALP: overview long term data 
Reference Institution Pts, n Time  
period 
Median follow-
up, months 
BRFS 
 
CRFS CSS 
Sooriakumaran43 Karolinska University, Stockholm, Sweden 944 2002-06 75.6 82.6%  
@ 9 yrs 
- - 
Abdollah44 Henry Ford Hospital, Detroit, MI, USA; Martini 
Clinic, Hamburg, Germany; San Raffaele 
University, Milan, Italy 
1100* 2002-13 49 50% 
@ 10 yrs 
87% 
@ 10 yrs 
- 
Diaz45 Henry Ford Hospital, Detroit, MI, USA 483 2001-03 120 73.1% 
@ 10 yrs 
- 98.8  
@ 10 yrs 
Abdel Raheem46 Yonsei University, Seoul, Korea 800 2005-10 64 76.4 
@ 5 yrs 
94.6% 
@ 5 yrs 
96.7% 
@ 5 yrs 
Suardi47 OLV Robotic Surgery Institute, Aalst, Belgium 184 - 67.5 81%  
@ 7 yrs 
- - 
Billia48 Guy's and St. Thomas' Hospitals, London, UK 175 - - 95.4% 
@ 5 yrs 
- 98.3% 
@ 5 yrs 
Liss49 University of California-Irvine, Orange, CA, 
USA 
289 2002-06 - 84.9%  
@ 5yrs 
- 99% 
@ 5 yrs 
BRFS=Biochemical recurrence free survival; CRFS=Clinical recurrence free survival; MFS *D’Amico high risk only 
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Table 3. Robotis versus open radical prostatectomy: high quality comparative studies to date 
Reference Study design Country N of patients Study 
period 
Endpoints Main findings  
Hu50 Retrospective observational 
study from SEER database 
USA 5,556 RALP 
vs 7,878 ORP 
2004-09 SM status; use of 
additional cancer 
therapy 
RALP associated with improved SM status for 
intermediate- and high-risk disease and less use 
of post-prostatectomy ADT and RT 
Haglind51 Prospective, controlled, non 
randomised multicenter 
(LAPPRO study) 
Sweden 1,847 RALP 
vs 778 ORP 
2008-11 UI and  EF @ 12 
months; SM status 
RALP modestly beneficial in preserving EF.  
No significant difference regarding UI or SM 
Leow52 Retrospective observational 
study from Premier Hospital 
database 
USA 311,135 RALP 
vs 318,458 
ORP 
2003-13 Outcomes and costs RALP confers a perioperative morbidity 
advantage; costs no longer significantly different 
when highest-volume surgeons and hospitals 
Seo53 Systematic review and meta-
analysis 
Korea 61 studies - Outcomes RALP better risk of UI, EF, and complications. 
SM and BCR rates comparable 
Yaxley54 RCT Australia 157 RALP vs 
151 ORP  
2010-14 UI and EF @ 6 and 
12 weeks  
Similar UI and EF outcomes 
Hu55 Retrospective observational 
study from SEER database 
USA 6,430 RALP 
vs 9,161 ORP 
2003-12 ACM, PCSM and use 
of additional cancer 
therapy 
RALP with less use of additional postoperative 
cancer therapies, and equivalent ACM and 
PCSM 
Thompson56 Prospective observational 
single surgeon study 
Australia 866 RALP vs 
686 ORP 
2006-12 Quality of life and 
SM 
 After a long learning curve, RALP has superior 
sexual, early urinary, and pT2 SM outcomes 
SEER= Surveillance Epidemiology and End Results; LAPPRO= Laparoscopic Prostatectomy Robot Open; RCT=Randomized controlled trial; RALP=Robot 
assisted laparoscopic radical prostatectomy; ORP=Open radical prostatectomy; SM=Surgical margin; UI=Urinary incontinence; EF=Erectile function; 
ADT=Androgen deprivation therapy; RT=Radiation therapy; BCR=Biochemical recurrence; ACM=All cause mortality; PCSM=Prostate cancer specific 
mortality 
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Table 4. Ongoing trials on radical surgical treatment of primary tumor in patients with oligometastatic prostate cancer (www.clinicaltrials.gov) 
Institution Name of 
trial 
Study 
design 
Treatment groups Study 
sample 
Primary endpoint Expected to be 
reported  
MD Anderson Cancer Center 
(USA) 
- RCT BST versus BST + RP or 
RT 
120 PFS 2018 
Oxford University (UK) TRoMbone RCT ADT versus ADT + RP 50 Feasibility to randomize 
@6 mo 
2018 
Martini Clinic (Germany) g-RAMPP RCT ADT versus ADT + RP 452 CSS 2025 
University of Vienna (Austria) - Prospective  
phase I-II 
RP 50 90 day complication rate 2021 
RCT= Randomized clinical trial; PFS=Progression free survival; CSS=Cancer specific survival; BST=Best systemic therapy; RP=Radical prostatectomy; 
RT=Radiation therapy; ADT=Androgen deprivation therapy 
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Table 5. Reported series on salvage lymph node dissection in recurrent prostate cancer 
Reference N of patients Imaging modality Surgical technique Followup Outcomes 
Suardi63 59 11C-choline PET/CT scan Open 81.8 mo^ BR: 59.3% 
8-yr BCR-free survival in patients with BR: 23% 
8-yr CR- and CSM-free survival: 38% and 81% 
Osmonov64 45 11C-choline PET/CT 42.7 mo* BCR-free survival: 73.3 %; CSS: 91.7%; OS: 80.6 % 
Winter65 13 11C-choline PET/CT 72 mo^ BR: 91%; Complete biochemical remission: 30% 
Montorsi66 16 11C-choline or (68)Ga-PSMA PET/CT Robotic 40 days BR: 33.3% 
de-Castro 
Abreu67 
10 Carbon-11 acetate PET/CT imaging 2 mo In patients with positive nodes, median PSA 
decreased by 83% 
BR=Biochemical response; BCR=Biochemical recurrence; CR=Clinical recurrence; CSM=Cancer specific mortality; CSS=Cancer specific survival; OS=Overall 
survival; ^=median; *=mean  
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Table 6. Focal therapy for prostate cancer: current evidence70  
Technique N of 
studies 
 N of 
patients 
Median follow-up, 
months 
Overall 
survival, % 
Disease specific 
survival, % 
Adverse event 
rate, % 
Continence 
rate, % 
Potency 
rate, % 
HIFU 13 346 12 100 100 1.5 100 88.6 
Cryotherapy 11 1,950 26  100 100 2.5 100 81.5 
PDT 3 116 6 100 100 10.6 na 88.4 
LITT 4 50 4.5 100 100 0 100 100 
Brachytherapy 2 339 61 na 99.9 na 95.2 na 
IRE 3 66 6 100 100 0 100 100 
HIFU=High intensity focused ultrasound; PDT=Photodynamic therapy; LITT=Laser interstitial thermotherapy; IRE=Irreversible electroporation; na=not 
available 
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Table 7. Sexual sparing techniques for radical cystectomy: summary of functional and oncological outcomes90-95  
Gender Techniques  N of 
studies 
N of 
cases 
Potency 
rate, % 
Sexual activity 
rate, % 
Daytime continence 
rate, % 
Nighttime continence 
rate, % 
Local 
recurrence rate, 
% 
Male Prostate sparing 12 1098 80-90 Na 88-100 31-98 10 
Seminal sparing 79 3 
Nerve sparing 29-78 6 
Female Genital organ 
preserving 
14 318 na 86.7 70.3 67.2 0-13 
Nerve sparing 
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Table 8. Focal therapy for kidney cancer:overview of available techniques132-137 
Technique Commercial names Mechanism Technique Major 
complication 
rate, % 
Failure 
rate, % 
FU, 
months 
Oncological 
outcomes 
Current status 
CRYO Endocare® 
(Healthtronics); Visual-
ICE® (Galil) 
Rapid cooling 
leading to cell 
necrosis 
Perc (CT 
guided); Lap 
(US guided) 
0-9.5 1.5-13 20-97.9 RFS: 77%;  
DFS: 85-97%;  
CSS: 98.5-
100% 
 
 
 
Established in 
clinical practice  RFA LeVeen® (Boston);  
Cool-tip® (Covidien);  
RITA StarBust® 
(Angiodynamics) 
Heat conduction 
inducing cellular 
death 
Perc (CT 
guided or MRI 
guided); Lap 
(US guided) 
8 2.5-10 27-65.6 RFS: 88-94.2% 
DFS: 61.9-
90.6% CSS: 
96.8-100% 
MWA Acculis® 
(Angiodynamics); 
Evident® (Medtronic); 
KY2000 (Kangyou 
Medical) 
Kinetic energy 
transformed into 
heat, leading to cell 
death 
Perc (CT 
guided); Lap 
(US guided) 
2-3 3-4.2% 6-32 RFS: 62-91.3% 
DFS: 92.3% 
CSS: 85.7-
100% 
 
 
 
 
Investigational 
IRE Naonoknife® 
(Angiodynamics) 
Electropulses 
creating nanoscale 
defects in cellular 
membrane 
Perc (CT or 
US guided); 
0 10 1-10 RFS: 90 
CRYO=Cryotherapy; RFA=Radiofrequency ablation; MWA=Microwave ablation; IRE=Irreversible electroporation; FU=Follow-up; RFS=Recurrence free survival; 
DFS=Disease free survival; CSS=Cancer specific survival 
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